ZA201401159B - Peg-interferon lambda 1 conjugates - Google Patents

Peg-interferon lambda 1 conjugates

Info

Publication number
ZA201401159B
ZA201401159B ZA2014/01159A ZA201401159A ZA201401159B ZA 201401159 B ZA201401159 B ZA 201401159B ZA 2014/01159 A ZA2014/01159 A ZA 2014/01159A ZA 201401159 A ZA201401159 A ZA 201401159A ZA 201401159 B ZA201401159 B ZA 201401159B
Authority
ZA
South Africa
Prior art keywords
conjugates
peg
interferon lambda
interferon
lambda
Prior art date
Application number
ZA2014/01159A
Inventor
Nhan Ho
Original Assignee
Nanogen Pharmaceutical Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanogen Pharmaceutical Biotechnology filed Critical Nanogen Pharmaceutical Biotechnology
Publication of ZA201401159B publication Critical patent/ZA201401159B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
ZA2014/01159A 2011-08-25 2014-02-14 Peg-interferon lambda 1 conjugates ZA201401159B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
VN201102222 2011-08-25
PCT/US2012/027317 WO2013028233A1 (en) 2011-08-25 2012-03-01 Peg-interferon lambda 1 conjugates

Publications (1)

Publication Number Publication Date
ZA201401159B true ZA201401159B (en) 2015-04-29

Family

ID=47746747

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/01159A ZA201401159B (en) 2011-08-25 2014-02-14 Peg-interferon lambda 1 conjugates

Country Status (9)

Country Link
EP (1) EP2748328A4 (en)
JP (1) JP2014525939A (en)
CN (1) CN103228792A (en)
AU (1) AU2012299423A1 (en)
BR (1) BR112014004302A2 (en)
CA (1) CA2846092A1 (en)
RU (1) RU2014111179A (en)
WO (1) WO2013028233A1 (en)
ZA (1) ZA201401159B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055343T2 (en) * 2016-02-19 2022-05-28 Eiger Biopharmaceuticals Inc Treatment of hepatitis delta virus infection with interferon lambda
EP3375452A1 (en) 2017-03-16 2018-09-19 Evangelos Andreakos Use of lambda interferons in the treatment of disorders and related diseases
RU2678332C1 (en) * 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Pegylated interferon lambda with high bioaccessability in oral use and method for production thereof
CN112245570A (en) 2019-07-22 2021-01-22 厦门特宝生物工程股份有限公司 Interferon-based disease treatment method
CN116761629A (en) 2021-01-21 2023-09-15 厦门特宝生物工程股份有限公司 Method and pharmaceutical composition for preventing cancer recurrence
EP4282427A1 (en) 2021-01-21 2023-11-29 Xiamen Amoytop Biotech Co., Ltd. Interferon-based cancer treatment method, and pharmaceutical combination

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CN1176137C (en) * 2002-01-15 2004-11-17 泛亚生物技术有限公司 Multi-arm fork type functional polyethylene glycol preparation method and its application in medicine
CN1927388B (en) * 2004-09-10 2011-02-02 北京金迪克生物技术研究所 Medicinal composition containing human interferon
CA2609205A1 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
US20080096252A1 (en) * 2005-10-04 2008-04-24 Zamost Bruce L Production and purification of il-29
CN101002942B (en) * 2007-01-08 2010-07-21 湖南大学 PEG type elaioplast nanometer particle
JP2011522834A (en) * 2008-06-05 2011-08-04 ザイモジェネティクス リミテッド ライアビリティ カンパニー Use of pegylated type III interferon for the treatment of hepatitis C

Also Published As

Publication number Publication date
WO2013028233A1 (en) 2013-02-28
EP2748328A1 (en) 2014-07-02
CA2846092A1 (en) 2013-02-28
JP2014525939A (en) 2014-10-02
AU2012299423A1 (en) 2014-03-06
BR112014004302A2 (en) 2017-06-20
EP2748328A4 (en) 2015-03-04
CN103228792A (en) 2013-07-31
RU2014111179A (en) 2015-09-27

Similar Documents

Publication Publication Date Title
ZA201401159B (en) Peg-interferon lambda 1 conjugates
FR2971446B3 (en) COIFF'RASOIR
GB201121094D0 (en) Concept 58
GB201120424D0 (en) Concept 66
GB201119762D0 (en) Concept 65
GB201117189D0 (en) Concept 64
GB201114530D0 (en) Concept 35
GB201114536D0 (en) Concept 39
GB201114472D0 (en) Concept 14
GB201114478D0 (en) Concept 11
GB201114480D0 (en) Concept 9
GB201114486D0 (en) Concept 6
GB201114487D0 (en) Concept 16
GB201114489D0 (en) Concept 12 12
GB201114502D0 (en) Concept 53
GB201114556D0 (en) Concept 42
GB201114511D0 (en) Concept 7
GB201114517D0 (en) Concept 15
GB201114519D0 (en) Concept 31
GB201114522D0 (en) Concept 32
GB201114523D0 (en) Concept 33
GB201114525D0 (en) Concept 3
GB201114529D0 (en) Concept 34
GB201114547D0 (en) Concept 23
GB201114532D0 (en) Concept 36